← Back to newsBODYPORT / NEWS & RESEARCH

March 8, 2022

Outpatient heart failure monitoring with a novel cardiac scale: tracking volume status, Journal of American College of Cardiology, JACC

We demonstrate the ability of our Cardiac Scale to monitor the fluid status of Heart Failure patients and intervene sooner compared to using weight or symptom changes.

‍

Download the PDF

Link to Paper

← All news and announcements Clinical evidence →

About Bodyport

Bodyport develops remote monitoring technologies for patients with fluid management-related health conditions. The FDA-cleared Bodyport Cardiac Scale measures weight, peripheral impedance, pulse rate, and balance through a simple daily measurement. Bodyport’s clinician-facing software combines longitudinal data into the Congestion Index, a clinical decision support tool that helps healthcare professionals identify and evaluate changes associated with worsening congestion. Based in San Francisco, the company is backed by top-tier investors including Boehringer Ingelheim Venture Fund, Terumo Medical, Initialized Capital, Playground Global, Rock Health, and Y Combinator. For more information, visit bodyport.com and follow the company on LinkedIn and Twitter.